Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

• Market Cap: ₹31.65B
• Dividend Yield: 0.03%
• Average Volume (3M): 2.36K
• Price to Earnings (P/E): 56.3
• Beta (1Y): 0.91
• Revenue Growth: 7.78%
• EPS Growth: -34.68%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.68
• Shares Outstanding: 100,282,510
• 10 Day Avg. Volume: 2,111
• 30 Day Avg. Volume: 2,356
• PEG Ratio: -2.39
• Price to Book (P/B): 5.63
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 124.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹366.00 ▲(8.24% Upside)

Gufic Biosciences' overall stock score is primarily influenced by its strong financial performance, despite challenges in cash flow and debt management. Technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth highlights the company's expanding market presence and successful product offerings, supporting long-term business sustainability.

Operational Efficiency

Strong margins reflect effective operational management, which can lead to sustained profitability and competitive advantage in the pharmaceutical industry.

Stable Balance Sheet

A stable balance sheet with increasing equity enhances financial stability, providing a strong foundation for future growth and investment opportunities.

Negative Factors

Net Income Volatility

Volatility in net income can lead to unpredictable earnings, which may affect investor confidence and the company's ability to reinvest in growth initiatives.

Inconsistent Cash Flow

Fluctuating cash flow can hinder the company's ability to fund operations and growth consistently, posing risks to financial stability and strategic planning.

High Debt Levels

Elevated debt levels can strain financial resources, limiting flexibility and increasing vulnerability to economic downturns or interest rate hikes.

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

How the Company Makes Money

Gufic Biosciences primarily generates revenue through the sale of its pharmaceutical products, which includes a wide range of generic and branded formulations. The company has established a revenue model based on both domestic and international sales, with exports contributing significantly to its earnings. Key revenue streams include sales from its injectable products, anti-infectives, and specialty medicines. Additionally, Gufic Biosciences has formed strategic partnerships and collaborations with various healthcare providers and institutions, which help enhance its market reach and drive additional revenue. The company's focus on research and development allows it to introduce new products that cater to evolving healthcare needs, further contributing to its financial growth.

Gufic Biosciences Limited Financial Statement Overview

Summary

Gufic Biosciences shows strong revenue growth and operational efficiency, but faces challenges with net income volatility and inconsistent cash flow. The balance sheet is stable but requires careful debt management.

Income Statement

Gufic Biosciences has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2020 to 2025. The gross profit margin and EBIT margin are solid, indicating efficient cost management and operational effectiveness. However, the net profit margin has shown some fluctuations, suggesting potential volatility in net income performance.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position with a consistent increase in stockholders' equity. However, the debt-to-equity ratio is moderately high, which may pose risks if not managed carefully. The equity ratio shows a healthy proportion of equity in the capital structure, enhancing financial stability.

Cash Flow

Gufic Biosciences exhibits inconsistent free cash flow performance, with notable fluctuations in free cash flow growth rates. The operating cash flow to net income ratio shows variability, suggesting challenges in converting income into cash flow. Despite periods of negative free cash flow, recent improvements indicate potential for recovery.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.41B	8.20B	8.07B	6.91B	7.79B	4.88B
Gross Profit	4.17B	2.97B	4.07B	3.51B	3.56B	2.31B
EBITDA	1.36B	1.38B	1.48B	1.37B	1.48B	857.85M
Net Income	618.64M	696.50M	861.36M	797.05M	958.40M	442.32M
Balance Sheet
Total Assets	0.00	11.69B	10.93B	8.61B	5.21B	3.92B
Cash, Cash Equivalents and Short-Term Investments	290.22M	290.22M	11.37M	286.02M	116.08M	62.01M
Total Debt	0.00	3.36B	3.33B	3.34B	643.87M	615.37M
Total Liabilities	-6.01B	5.68B	5.60B	5.13B	2.52B	2.19B
Stockholders Equity	6.01B	6.01B	5.33B	3.48B	2.69B	1.73B
Cash Flow
Free Cash Flow	0.00	270.96M	-1.20B	-2.14B	187.86M	748.51M
Operating Cash Flow	0.00	1.03B	-74.57M	-265.87M	1.06B	872.51M
Investing Cash Flow	0.00	-717.09M	-1.02B	-1.91B	-945.89M	-66.93M
Financing Cash Flow	0.00	-163.26M	823.81M	2.34B	-62.44M	-786.18M

Gufic Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 338.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 338.15 is above the 20-day moving average (MA) of 335.88, below the 50-day MA of 339.25, and below the 200-day MA of 356.08, indicating a bearish trend. The MACD of -6.74 indicates Positive momentum. The RSI at 36.95 is Neutral, neither overbought nor oversold. The STOCH value of 20.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORCHPHARMA	64 Neutral	₹36.65B	71.20	―	―	-9.23%	-56.08%
IOLCP	60 Neutral	₹22.26B	19.24	―	0.97%	5.74%	16.06%
HIKAL	58 Neutral	₹26.50B	259.92	―	0.58%	-6.72%	-86.26%
GUFICBIO	57 Neutral	₹31.65B	56.32	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹21.18B	21.41	―	0.49%	-0.29%	-29.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	40 Neutral	₹19.83B	-17.95	―	0.08%	-2.81%	-444.69%

Gufic Biosciences Limited Corporate Events

Gufic Biosciences to Appeal GST Penalty Order, Sees No Material Impact

Gufic Biosciences Limited has disclosed that it received an order from the Office of the Superintendent CGST, Ghaziabad, imposing penalties totaling about Rs 15.64 lakh for alleged excess input tax credit claims and short payment of GST for financial years 2018-19 to 2022-23. The company plans to appeal the order and, based on its assessment and legal advice, does not expect any material impact on its financial operations or other activities, suggesting limited immediate implications for shareholders and business continuity.

Gufic Biosciences Releases Earnings Call Audio

Gufic Biosciences Limited announced that the audio recording of its recent earnings conference call, held on November 17, 2025, has been uploaded to the company’s website. This move ensures transparency and provides stakeholders with easy access to the company’s financial discussions, potentially impacting investor confidence and market perception.

Gufic Biosciences Schedules Analyst and Investor Meeting

Gufic Biosciences Limited has announced a scheduled meeting with analysts and institutional investors on November 21, 2025, at the JM Financial India Xchange in Mumbai. The meeting aims to discuss already published information, ensuring no unpublished price-sensitive information is shared, reflecting the company’s commitment to transparency and regulatory compliance.